What the BBs are doing epitomizes the activist investor approach. This is very good for all of us. The BBs aren't there to cure cancer etc. They are there to make money. Period. You can bet that they are keeping their eye focused on getting that done. They have their hands deep into this.
Being genuinely excited about a company's prospects does not equate to being "married" to a stock. Meanwhile, you're slipping. You have yet to provide anything concrete. I'm always happy to listen to opposing views. So far you haven't offered anything. You've simply spent lots of time being vague and negative.
How many times have we've seen this MO? Starts off soft and ambiguous simply to pee on the parade and then progresses from there in order to create doubt and uncertainty. I have no problem with contrarian points of view but only if they are founded in facts. The "what if' game has no end and is designed simply to create an atmosphere of negativity. We'll see angry posts from this poster as they always fail to maintain civility at some point. Then the veil will completely fall off.
LOL, The CEO's open market stock purchase seems to bother you greatly. Were you short yesterday? Seems you are frustrated with the move.
If that were the case he would be content to just sit on his options and collect his salary. In biotech the majority of CEOs never make an open market purchase of this magnitude in addition to their granted options.
He bought large and he bought early because he won't be able to buy on the open market very shortly. Developments coming shortly will keep him from buying due to insider trading rules/laws. Very good sign. Supreme confidence.
Strategic partnerships are all ready being lined up. Bet on it. IDRA, despite a fantastic management team will need outside collaboration to design and implement combination trials on a large and meaningful scale. I think the purchase of shares by the CEO shows confidence in the ability of his team to get this done. Partners will be drawn to IDRA due to the promise of the pipeline.
Milano's resume include taking ViroPharma all the way. During that journey ViroPharma had strategic relationships with GlaxoSmithKline, Shering-Plough and Sanofi - Aventis as well as an acquisition/merger with Lev Pharma.....before being bought by Shire for 4.2 billion. Expect news soon of a partnership(s).
Short interest went up substantially on the from 10/31 to 11/14. Could be shorts were caught flat footed and are covering on the heels of the traders that are taking Friday afternoon profits and exiting their positions. The pin around $4.00 seems pretty artificial. Also makes me wonder if they are going to float a secondary.....at $4.00
There is no such thing as a shelf offering. You file a shelf with the SEC for future secondary offerings. A "shelf" is not an ATM.
I actually wrote something similar just not nearly as well, lol. I think this explains the lack of run up into results for SP-333. I also think that SGYP telegraphed your thoughts when they did the convertible note deal. To my knowledge they never mentioned SP-333 development, only plecanatide.
However, lets not rush to judgement. We only have top line data here. The anti inflammatory qualities of SP-333 have yet to be divulged/determined. That information will be very important to the value of SP-333
Less than 75,000 shares traded in 1 1/2 hours? Geez I'd hate to see what it would be like if we didn't have the SP-333 trial results pending neat term. This is worse than watching paint dry.
I know that Plecanatide and SP-333 are in trial for different indications but since SP-333 is being touted by the company as the next generation of "proprietary analog of uroguanylin", I wonder if this is a no win situation in some minds. In other words will success of SP-333 be seen as accretive to the success of the company if trials go well or simply a future replacement for Plecanatide, in essence negating all the time, effort and money put forth to develop Plecanatide? If the trials for SP-333 don't go extremely well or simply disappoint then Plecanatide stands on its own. Differentiated from the competition for sure but perhaps not enough to move the needle. Just thinking out loud, ala horse.
I wouldn't hold my breath for any kind of investigation and/or enforcement action. SGYP isn't the first and won't be the last to be subject to this kind of manipulation, typically with no redress. Some covering may have taken place from the lows but the real question is what is their game plan now? I guess until volume/demand picks up, there is little incentive to cover.
I said as much earlier. Quite plausible from my perspective. No one allocates resources and effort to this extent, to bring down a stock, without a motive and game plan. There certainly is a back story to this saga.
There is no incentive to do the conversion without significant share appreciation when you're earning 7.5% on the notes UNLESS the notes fall into the hands of whatever entities have the short position. At this point we don't know who to trust. Deerfield certainly isn't an outfit I would trust, based on past experience. Suffice it to say, retail shareholders certainly don't have an advocate in their corner. We're simply along for the ride.
Different ways to look at this. If a partnership or takeout were on the horizon, short or medium term, there would have been no reason to secure 200 million in cash. On the other hand, partnership and takeout negotiations can be brutal and all but impossible to negotiate unless from a position of financial strength. The one thing that caught my eye in the press release detailing the note sale was that the funds were raised to further the development of plecanatide with an obvious lack of mention of SP-333. That simply could be because P2 results are unknown for SP-333 but I thought it odd there was no mention. Maybe the price action has me paranoid and over thinking the situation.